美国 · 平台与数据 · Finviz

Travere's FILSPARI Tops $200 Million As Revenue Beats, But A Deal Charge Drives An EPS Miss And Softer New-Patient Starts Cloud The Ramp

来源：Finviz · 美国 9 小时前

Revenue went the other way. It reached $224.56 million, beating the $192.52 million consensus by 16.6% and growing 36.2% year over year. FILSPARI net sales crossed $200 million…

在 Finviz 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (finviz.com)

Travere's FILSPARI Tops $200 Million As Revenue Beats, But A Deal Charge Drives An EPS Miss And Softer New-Patient Starts Cloud The Ramp

推荐阅读

BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 52-Week Low - Here's What Happened

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Travere's FILSPARI Tops $200 Million As Revenue Beats, But A Deal Charge Drives An EPS Miss And Softer New-Patient Starts Cloud The Ramp

分享

推荐阅读

BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 52-Week Low - Here's What Happened

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Here’s why Palantir’s stock is down despite a ‘bombastic’ quarter

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows